Treatment of Siewert type II adenocarcinoma of the esophagogastric junction: the perspectives from thoracic surgery.
10.3760/cma.j.cn441530-20211222-00526
- Author:
Zhen Yan LI
1
;
Yi Min GU
2
;
Wen Ping WANG
2
;
Long Qi CHEN
2
Author Information
1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China.
2. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Adenocarcinoma of the esophagogastric junction;
Comprehensive treatment;
Endoscopic surgery;
Lymph node dissection;
Residual margin;
Siewert classification;
Surgical approach;
Thoracoscopy surgery
- MeSH:
Adenocarcinoma/pathology*;
Esophageal Neoplasms/surgery*;
Esophagogastric Junction/surgery*;
Gastrectomy;
Humans;
Lymph Node Excision;
Retrospective Studies;
Stomach Neoplasms/surgery*;
Thoracic Surgery
- From:
Chinese Journal of Gastrointestinal Surgery
2022;25(2):109-113
- CountryChina
- Language:Chinese
-
Abstract:
A greater controversy remains in clinical diagnosis and treatment of Siewert type II adenocarcinoma of esophagogastric junction (AEG), compared with Siewert type I and III AEG. In 2018, the first edition of Chinese Expert Consensus on the Surgical Treatment for Adenocarcinoma of Esophagogastric Junction was published in the Chinese Journal of Gastrointestinal Surgery. In the past few years, the advance in minimally invasive thoracoscopic surgery has been proven to reduce thoracic trauma in Siewert type II AEG. Meanwhile, distal thoracic esophagectomy can achieve more complete resection, and upper abdomen-right thoracic approach can ensure the mediastinal lymph node dissection and improve long-term survival. The concept and practice of endoscopic surgery and the comprehensive treatment also give new supplements to the treatment regimen of Siewert type II AEG. More clinical researches should be conducted to address the surgical residual safety and lymph node dissection issues.
